146 related articles for article (PubMed ID: 7795269)
1. Multidrug resistance.
Tsuruo T; Tomida A
Anticancer Drugs; 1995 Apr; 6(2):213-8. PubMed ID: 7795269
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of multidrug resistant tumors and chemotherapeutic approaches against the resistant tumors].
Tsuruo T
Yakugaku Zasshi; 1997 Aug; 117(8):455-67. PubMed ID: 9306724
[TBL] [Abstract][Full Text] [Related]
3. [MDR reversing drugs for clinical development].
Tsuruo T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):962-7. PubMed ID: 8002634
[TBL] [Abstract][Full Text] [Related]
4. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
[TBL] [Abstract][Full Text] [Related]
5. Circumvention of multidrug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact?
Beck WT
J Natl Cancer Inst; 1995 Jan; 87(2):73-5. PubMed ID: 7707392
[No Abstract] [Full Text] [Related]
6. Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil.
Shrivastava P; Hanibuchi M; Yano S; Parajuli P; Tsuruo T; Sone S
Cancer Chemother Pharmacol; 1998; 42(6):483-90. PubMed ID: 9788575
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies specific for P-glycoprotein.
Okochi E; Iwahashi T; Tsuruo T
Leukemia; 1997 Jul; 11(7):1119-23. PubMed ID: 9205000
[TBL] [Abstract][Full Text] [Related]
8. Re: Circumvention of multi-drug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact?
Baccarani M
J Natl Cancer Inst; 1995 Jun; 87(11):845-6. PubMed ID: 7791235
[No Abstract] [Full Text] [Related]
9. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance.
Nishioka Y; Yano S; Fujiki F; Mukaida N; Matsushima K; Tsuruo T; Sone S
Int J Cancer; 1997 Apr; 71(2):170-7. PubMed ID: 9139838
[TBL] [Abstract][Full Text] [Related]
11. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
12. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
Nokihara H; Yano S; Nishioka Y; Hanibuchi M; Higasida T; Tsuruo T; Sone S
Jpn J Cancer Res; 2001 Jul; 92(7):785-92. PubMed ID: 11473730
[TBL] [Abstract][Full Text] [Related]
13. Monocyte chemoattractant protein-1 gene modification of multidrug-resistant human lung cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID mice.
Nokihara H; Nishioka Y; Yano S; Mukaida N; Matsushima K; Tsuruo T; Sone S
Int J Cancer; 1999 Mar; 80(5):773-80. PubMed ID: 10048981
[TBL] [Abstract][Full Text] [Related]
14. [Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209].
Naito M; Nakanishi O; Tsuruo T
Nihon Rinsho; 1997 May; 55(5):1122-7. PubMed ID: 9155163
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
17. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
18. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance.
Atadja P; Watanabe T; Xu H; Cohen D
Cancer Metastasis Rev; 1998 Jun; 17(2):163-8. PubMed ID: 9770112
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance in cancer chemotherapy.
Patel NH; Rothenberg ML
Invest New Drugs; 1994; 12(1):1-13. PubMed ID: 7960599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
